5-Amino-1MQ 101: The NNMT Inhibitor Explained

The Basics

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme that plays a central role in cellular energy metabolism and fat storage. Unlike most peptides in the research space, 5-Amino-1MQ is technically not a peptide at all; it's a quinolinium derivative. But it's researched alongside metabolic peptides because it addresses the same downstream goals: fat loss, metabolic efficiency, and body composition.

Developed and studied primarily at the University of Texas, 5-Amino-1MQ targets an enzyme that is overexpressed in adipose tissue in obese subjects, making it a mechanistically interesting approach to metabolic research that operates upstream of the pathways targeted by compounds like AOD-9604 or Tesamorelin.

Not a Peptide — But Why It's Here

5-Amino-1MQ is a small molecule, not a peptide. It's included in peptide research discussions because it's sold by the same vendors, researched in similar contexts, and targets overlapping metabolic goals. The mechanism — NNMT inhibition — is distinct from all other compounds in this space.

NNMT

Enzyme Target

NAD+

Pathway Effect

Oral

Route (research)

Small molecule

Classification

Mechanism

How Does 5-Amino-1MQ Work?

To understand 5-Amino-1MQ, you need to understand NNMT. Nicotinamide N-methyltransferase is an enzyme that methylates nicotinamide (a form of vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor. This reaction consumes SAM and produces N-methylnicotinamide and S-adenosylhomocysteine.

NNMT is highly expressed in adipose tissue, particularly in obesity. When NNMT is overactive, it creates two metabolic problems simultaneously:

SAM depletion: SAM is the universal methyl donor for hundreds of cellular reactions. NNMT overconsumption of SAM depletes the pool available for other processes including gene regulation and metabolism
NAD+ precursor diversion: By consuming nicotinamide, NNMT diverts a precursor that would otherwise contribute to NAD+ synthesis — reducing cellular NAD+ levels and impairing mitochondrial function

What NNMT Inhibition Does

By blocking NNMT, 5-Amino-1MQ restores both SAM availability and NAD+ precursor flux. In adipose tissue specifically, this produces several downstream effects studied in preclinical models:

Increased NAD+ levels → enhanced mitochondrial activity → greater fat oxidation
Restored SAM → normalized epigenetic methylation patterns that regulate fat cell metabolism
Reduced adipocyte differentiation (fewer new fat cells forming)
Increased resting metabolic rate in treated animals

The NAD+ Connection

NNMT inhibition is functionally related to NAD+ supplementation (NMN, NR, NAD+) because both approaches increase cellular NAD+ availability. But 5-Amino-1MQ targets the enzyme consuming the precursor rather than supplementing the end product — an upstream vs downstream approach to the same problem.

Research Applications

What Is 5-Amino-1MQ Studied For?

Obesity and fat loss: The primary research focus — diet-induced obesity models show significant fat mass reduction with 5-Amino-1MQ without caloric restriction in several studies
Metabolic syndrome: Improvements in insulin sensitivity, lipid profiles, and inflammatory markers in obese animal models
NAD+ restoration: As an indirect NAD+ booster, research overlaps with the broader NAD+ precursor literature on aging and metabolic function
Adipogenesis inhibition: Reduction in the formation of new adipocytes from precursor cells
Muscle preservation: Some preclinical data suggests 5-Amino-1MQ may have muscle-sparing effects during fat loss — a meaningful distinction from purely catabolic approaches

Where 5-Amino-1MQ Stands Out

Most fat-loss peptides (AOD-9604, Tesamorelin) work by modulating growth hormone signaling. 5-Amino-1MQ works entirely upstream — at the epigenetic and metabolic enzyme level. For researchers interested in the metabolic machinery of fat storage rather than hormonal signaling, it's a fundamentally different tool.

Quick Comparison

5-Amino-1MQ vs Other Fat Loss Compounds

Factor	5-Amino-1MQ	AOD-9604	Tesamorelin
Mechanism	NNMT inhibition → NAD+ / SAM restoration	β3-adrenergic receptor activation → lipolysis	GHRH analog → GH → IGF-1 → visceral fat reduction
Classification	Small molecule	Peptide	Peptide
Primary fat target	General adipose (all depots)	Subcutaneous + visceral	Visceral specifically
Metabolic rate effect	Yes (preclinical)	Limited	Indirect via GH
Muscle preservation data	Some preclinical evidence	Minimal	Yes (GH-related)
Route	Oral or SubQ	SubQ	SubQ
Clinical trials	None yet	Phase 2 (completed)	Phase 3 (FDA approved)

View 5-Amino-1MQ Pricing & Vendor Data

COA-verified vendor pricing with promo codes. Both S1 Research and Tegridy Research carry 5-Amino-1MQ.

View Pricing → Dosage Calculator

Common Questions

FAQ

Is 5-Amino-1MQ the same as NMN or NR?

No — but they're related. NMN and NR are NAD+ precursors that directly supplement the NAD+ pathway. 5-Amino-1MQ inhibits NNMT, the enzyme that consumes NAD+ precursors before they reach that pathway. They both increase cellular NAD+ availability but from opposite ends: NMN/NR add more precursor; 5-Amino-1MQ stops an enzyme from wasting what's already there.

Can 5-Amino-1MQ be taken orally?

Yes — as a small molecule rather than a peptide, 5-Amino-1MQ has better oral bioavailability than most compounds in this space. Preclinical studies have used oral administration successfully. Research community protocols use both oral and SubQ routes, with oral being common given the practical advantage.

Why is NNMT overexpressed in obesity?

NNMT expression in adipose tissue increases as fat mass increases, creating a feedback loop: more fat cells → more NNMT → more SAM/NAD+ depletion → impaired metabolic function → more fat accumulation. 5-Amino-1MQ research targets this loop directly rather than simply stimulating lipolysis of existing fat.

How does 5-Amino-1MQ pair with GLP-1 agonists like Retatrutide?

This is an area of growing research interest. GLP-1 agonists reduce caloric intake and improve insulin signaling. 5-Amino-1MQ targets metabolic enzyme activity and fat cell biology. The mechanisms don't overlap, suggesting complementary rather than redundant effects in combined protocols — though direct combination data in humans doesn't exist yet.

Research purposes only. 5-Amino-1MQ is a research compound not approved for human use. This content is for educational reference only and does not constitute medical advice.

Keep Reading